Chronic spontaneous urticaria: news about problem and treatment (literature review)

Abstract

Despite advances in understanding the mechanisms of development of chronic urticaria, in a large percentage of cases there are unsatisfied treatment results, there is no possibility of controlling the disease. Currently, the treatment of patients with chronic urticaria is of a staged nature. In 2014, omalizumab was registered in Russia for extended indications, which makes it possible to achieve control of the refractory form of chronic spontaneous urticaria. The article presents data on the effectiveness and safety of omalizumab. According to the results of numerous studies, omalizumab showed a quick and pronounced effect in the treatment of patients with chronic spontaneous urticaria who do not respond to therapy with H1-receptor blockers. The issues of effective dose, safety and tolerability of the therapy, timing of evaluating the effectiveness, duration of the course and tactics of managing patients with a partial response or lack of response were considered.